[go: up one dir, main page]

WO2009007680A3 - Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders - Google Patents

Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders Download PDF

Info

Publication number
WO2009007680A3
WO2009007680A3 PCT/GB2008/002249 GB2008002249W WO2009007680A3 WO 2009007680 A3 WO2009007680 A3 WO 2009007680A3 GB 2008002249 W GB2008002249 W GB 2008002249W WO 2009007680 A3 WO2009007680 A3 WO 2009007680A3
Authority
WO
WIPO (PCT)
Prior art keywords
statin
treatment
mast cell
combinations
cell inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/002249
Other languages
French (fr)
Other versions
WO2009007680A2 (en
Inventor
Carl-Johan Dalsgaard
Johan Raud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardoz AB
Original Assignee
Cardoz AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz AB filed Critical Cardoz AB
Publication of WO2009007680A2 publication Critical patent/WO2009007680A2/en
Publication of WO2009007680A3 publication Critical patent/WO2009007680A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

There is provided combination products comprising (a) a mast cell inhibitor, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a statin, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in the treatment of atherosclerosis and related conditions.
PCT/GB2008/002249 2007-07-11 2008-06-25 Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders Ceased WO2009007680A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92973307P 2007-07-11 2007-07-11
US60/929,733 2007-07-11

Publications (2)

Publication Number Publication Date
WO2009007680A2 WO2009007680A2 (en) 2009-01-15
WO2009007680A3 true WO2009007680A3 (en) 2009-03-12

Family

ID=38669363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002249 Ceased WO2009007680A2 (en) 2007-07-11 2008-06-25 Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders

Country Status (1)

Country Link
WO (1) WO2009007680A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118078814A (en) * 2024-01-15 2024-05-28 青岛海洋生物医药研究院股份有限公司 Application of Amlexanox in the preparation of medicines for treating psoriasis and inflammation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086349A (en) * 1975-07-30 1978-04-25 Mitsubishi Yuka Pharmaceutical Co., Ltd. Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma
US20020103219A1 (en) * 2000-10-05 2002-08-01 Jeremy Jacob Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders
US6585995B1 (en) * 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
WO2005092264A1 (en) * 2004-03-10 2005-10-06 Ethicon, Inc. Drug-enhanced adhesion prevention
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0766963B1 (en) 1994-05-31 2000-04-26 Mitsubishi-Tokyo Pharmaceuticals, Inc. Arteriosclerosis depressant
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
WO2004002530A1 (en) 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. Remedy for chronic disease
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
TW200408393A (en) 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
WO2004071531A1 (en) 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
US9066912B2 (en) 2003-11-17 2015-06-30 Ethicon, Inc. Drug-enhanced adhesion prevention
US20070014733A1 (en) 2005-01-31 2007-01-18 O'donnell John P Hydroxylated nebivolol metabolites

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086349A (en) * 1975-07-30 1978-04-25 Mitsubishi Yuka Pharmaceutical Co., Ltd. Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma
US6585995B1 (en) * 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
US20020103219A1 (en) * 2000-10-05 2002-08-01 Jeremy Jacob Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders
WO2005092264A1 (en) * 2004-03-10 2005-10-06 Ethicon, Inc. Drug-enhanced adhesion prevention
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
"Statins slow the progression of atherosclerosis and improve vascular function", EVIDENCE-BASED CARDIOVASCULAR MEDICINE, CHURCHILL LIVINGSTONE, vol. 9, no. 2, June 2005 (2005-06-01), pages 145, XP004909756, ISSN: 1361-2611 *
ENDRES ET AL: "Statins: Potential new indications in inflammatory conditions", ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER, vol. 7, no. 1, April 2006 (2006-04-01), pages 31 - 35, XP005350024, ISSN: 1567-5688 *
ISAJI M ET AL: "TRANILAST INHIBITS THE PROLIFERATION, CHEMOTAXIS AND TUBE FORMATIONOF HUMAN MICROVASCULAR ENDOTHELIAL CELLS IN VITRO AND ANGIOGENESIS IN VIVO", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 122, no. 6, November 1997 (1997-11-01), pages 1061 - 1066, XP000997892, ISSN: 0007-1188 *
JONES N L ET AL: "Ketotifen therapy for acute ulcerative colitis in children: A pilot study", DIGESTIVE DISEASES AND SCIENCES, PLENUM PUBLISHING CO, US, vol. 43, no. 3, March 1998 (1998-03-01), pages 609 - 615, XP008086243, ISSN: 0163-2116 *
LEVESQUE H: "Nonlipid effects of statins on atherosclerosis", REVUE DE MEDECINE INTERNE, CMR, ASNIERES, FR, vol. 25, no. 11, November 2004 (2004-11-01), pages 783 - 785, XP004608693, ISSN: 0248-8663 *
MARSHALL J K ET AL: "Ketotifen treatment of active colitis in patients with 5-aminosalicylate intolerance", CANADIAN JOURNAL OF GASTROENTEROLOGY, MEDICARE PUBL., OAKVILLE, CA, vol. 12, no. 4, 1998, pages 273 - 275, XP008086245, ISSN: 0835-7900 *
MATSUMURA ET AL: "Suppression of atherosclerotic development in watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast", MEDLINE, 23 February 1999 (1999-02-23), XP002953929 *
MINOCHA A ET AL: "Role of ketotifen in pathogenesis of chronic ulcerative colitis", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 104, no. 4 SUPPL, 1993, pages A746, XP008086242, ISSN: 0016-5085 *
NOBUHIDE O ET AL: "Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease", GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, GB, vol. 56, no. 4, April 2007 (2007-04-01), pages 599 - 600, XP008086231, ISSN: 0017-5749 *
SAIURA A ET AL: "Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 433, no. 2-3, 21 December 2001 (2001-12-21), pages 163 - 168, XP008086230, ISSN: 0014-2999 *
SAMSON K T R ET AL: "Inhibitory effects of fluvastatin on cytokine and chemokine production by peripheral blood mononuclear cells in patients with allergic asthma", CLINICAL AND EXPERIMENTAL ALLERGY, BLACKWELL SCIENTIFIC PUBLICATIONS, LONDON, GB, vol. 36, no. 4, April 2006 (2006-04-01), pages 475 - 482, XP002446080, ISSN: 0954-7894 *
SHIMIZU T ET AL: "INHIBITORY EFFECTS OF AZELASTINE AND TRANILAST ON LEUKOTRIENE B4 AND LEUKOTRIENE C4, GENERATION BY RAT COLONIC MUCOSA", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE MEDICAL JOURNALS,, GB, vol. 53, no. 5, 1995, pages 355 - 358, XP001042184, ISSN: 0952-3278 *
TEH L G ET AL: "Does the addition of ketotifen to non-steroidal anti-inflammatory drugs confer any additional benefit in rheumatoid arthritis?", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, BLACKWELL SCIENTIFIC PUBL, GB, vol. 17, no. 2, 1984, pages 157 - 159, XP008086082, ISSN: 0306-5251 *
TUNON ET AL: "Endothelial Dysfunction, Inflammation, and Statins: New Evidence", REVISTA ESPANOLA DE CARDIOLOGIA, EDICIONES DOYMA S.A., BARCELONA, ES, vol. 57, no. 10, October 2004 (2004-10-01), pages 903 - 905, XP005643149, ISSN: 1885-5857 *
VAUGHAN C J ET AL: "THE EVOLVING ROLE OF STATINS IN THE MANAGEMENT OF ATHEROSCLEROSIS", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 35, no. 1, January 2000 (2000-01-01), pages 1 - 10, XP001070368, ISSN: 0735-1097 *
YAMADA N ET AL: "MY-1250, a major metabolite of the anti-allergic drug repirinast, induces phosphorylation of a 78-kDa protein in rat mast cells", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 44, no. 6, 25 September 1992 (1992-09-25), pages 1211 - 1213, XP023732179, ISSN: 0006-2952, [retrieved on 19920925] *
ZHANG W ET AL: "Development of new therapeutic effect and mechanism of tranilast", ZHONGGUO XIN YAO YU LINCHUANG ZAZHI - CHINESE JOURNAL OF NEW DRUGS AND CLINICAL REMEDIES, SHANGHAI SHI YIYAO GUANLIJU KE-JI QINGBAO YANJIUSUO ZHONGGUO, CN, vol. 23, no. 11, November 2004 (2004-11-01), pages 795 - 798, XP008086232, ISSN: 1007-7669 *

Also Published As

Publication number Publication date
WO2009007680A2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2009007673A3 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist
EP2497470B8 (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2007052285A8 (en) Universal knowledge management and desktop search system
EP2489657A3 (en) Inhibitors of histone deacetylase
WO2009007675A3 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist
EP1847164B8 (en) Split power input to chiller
WO2007047604A3 (en) Sirt1 inhibition
MX2009006507A (en) New combination for use in the treatment of inflammatory disorders.
AU2007337830A8 (en) Benzenesulfonamide derivatives as HIV protease inhibitors
WO2009007679A3 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
WO2009007674A3 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast
WO2009007680A3 (en) Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders
IL201168A0 (en) New combination for use in the treatment of inflammatory disorders
WO2007035964A3 (en) Vigabatrin bioisoteres and related methods of use
AU2005100796A4 (en) Hexagonal Rotating Pool Table
HK1109775A (en) Amino-pyridines as inhibitors of beta-secretase
AU2005100666A4 (en) Laptop stable table
HK1114093A (en) Imidazolo-5-yl-2-anilo-pyrimidines as agents for the inhibition of cell proliferation
AU2007904452A0 (en) Water saving wok
HK1126196A (en) 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation
AU2005907255A0 (en) Utility cross-arm
HK1113138A (en) The preparation and use of compounds as protease inhibitors
HK1114765A (en) The preparation and use of compounds as protease inhibitors
AU2005906584A0 (en) Use of Inhibitors of Prolyl-4-Hydroxylases
HK1139146A (en) Heterocyclic compounds and use thereof as erk inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08775800

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08775800

Country of ref document: EP

Kind code of ref document: A2